An Early Phase 1 interventional study of Potassium citrate and Sodium bicarbonate in Kidney Stone, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University of Texas Southwestern Medical Center · Early Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.
Among the 193 studies in Kidney Calculi with a site in United States, this one is the 125th largest by planned enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 22 of the 57 other live ones, and was the 115th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:
Calyxo, Inc. · Sites in United States
Ages 18+
YolTech Therapeutics Co., Ltd · Sites in United States
Ages 6+
Children's Hospital of Philadelphia · Sites in United States
Ages 6+
Ohio State University · Sites in United States
Ages 18+
Calyxo, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 47 across the 165 interventional studies, 122 across the 28 observational. Of the 116 that completed or were terminated, 51 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 193 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 5 studies filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
17 of the studies in Kidney Calculi with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07296835University of Kansas Medical CenterSurgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope | 2026-11 |
| NCT04651088University of Texas Southwestern Medical CenterComparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet | 2026-12 |
| NCT05993546The Cleveland ClinicRandomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis | 2026-12 |
| NCT04333745University of Alabama at BirminghamInfluence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers | 2026-12-01 |
| NCT04603898University of Alabama at BirminghamOxalate Formation From Ascorbic Acid | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 193 studies in Kidney Calculi with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.
Kidney stones are a common medical problem, occurring in almost 10% of people in the United States1. Furthermore, 50% of patients will recur within 10 years2. Metabolic testing is advised in recurrent stone formers, as well as those considered high risk, to assess for a specific abnormality which may prompt intervention to prevent future stone formation. Non-surgical interventions include both dietary counselling, as well as pharmacotherapy.
One of the most commonly prescribed class of pharmacotherapies is alkali therapy which can be used to both increase the urinary pH and raise the urine citrate levels. This is particularly useful as correction of very acidic urinary pH (\<5.5) can counteract uric acid crystallization thereby preventing or even dissolving uric acid stones3. Further, citrate has been shown to be a potent inhibitor of calcium stones by binding to the calcium directly4 and inhibiting crystal nucleation, thereby reducing calcium stone formation5,6.
The most commonly utilized preparation of alkali therapy is potassium citrate which has been shown to prevent stone formation better than sodium citrate7. Unfortunately, some forms of potassium citrate (crystal packets) have become unavailable, and the slow release form of potassium citrate (UroCit-K) now exceeds $15/day in cost8. There have been multiple alternative alkali therapies that have been used in place of potassium citrate, including both medical foods and prescription medications, but with little evidence to support their use. A pilot study in order to quantify the metabolic effects of these agents and compare them to potassium citrate will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Controlled metabolic diet arm.
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate
Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
650mg tabs. Take 3 tabs twice daily.
One packet is taken with 170ml of water. Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
24 hour urine volume
Total urine volume
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine volume
Total urine volume
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine creatinine
Urine creatinine
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine creatinine
Urine creatinine
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine calcium
urine calcium
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine calcium
urine calcium
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine potassium
Urine potassium
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine potassium
Urine potassium
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine sodium
Urine sodium
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine sodium
Urine sodium
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hours urine citrate
Urine citrate
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine citrate
Urine citrate
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hours urine uric acid
Urine uric acid
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine uric acid
Urine Uric Acid
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hours urine oxalate
Urine oxalate
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine oxalate
Urine oxalate
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hours urine magnesium
Urine magnesium
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine magnesium
Urine magnesium
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hours urine ammonia
Urine ammonia
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hours urine ammonia
Urine ammonia
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 Hour Urine pH
Overal Urine pH from 24h urine sample.
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 Hour Urine pH
Overal Urine pH from 24h urine sample.
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine phosphorus
Urine phosphorus
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine phosphorus
Urine phosphorus
Time frame: Change from baseline (Day 4) to end of study (day 12)
24 hour urine sulfate
Urine sulfate
Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
24 hour urine sulfate
Urine sulfate
Time frame: Change from baseline (Day 4) to end of study (day 12)
# of patient who adherence to 100% Medication
Patient's adherence to medication for duration of study.
Time frame: At the end of study approximately 10 weeks after start of study.
Total out of pocket cost
Calculate and compare treatment costs for the different interventions (in American dollars).
Time frame: At the end of study approximately 10 weeks after start of study.
Patient's Satisfaction Survey
Patient satisfaction survey, adapted from the Treatment Satisfaction Questionnaire for Medication-14. Patients are queried on their satisfaction, with 9 questions for each medication.
Time frame: At the end of study approximately 10 weeks after start of study.
Patient's GI Distress
Patient's GI distress symptom scale measures patients GI distress. There are 18 questions with descriptive answers ranging from "none", "mild", "moderate", "quite a lot" and "unbearable". There are no numerical scores, rather just descriptive scores. "None" means no GI distress, "unbearable" means that you are in a lot of distress from your GI symptoms.
Time frame: At the end of study approximately 10 weeks after start of study.
Plan to share: No
Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Potassium Citrate · Sodium Bicarbonate · Potassium bicarbonate
University of Texas Southwestern Medical Center →